The platform will undergo maintenance on Sep 14 at about 7:45 AM EST and will be unavailable for approximately 2 hours.
2005
DOI: 10.1159/000087471
|View full text |Cite
|
Sign up to set email alerts
|

Severe Hyperinsulinaemic Hypoglycaemia in a Baby Born to a Mother Taking Oral Ritodrine Therapy for Preterm Labour

Abstract: Hyperinsulinism of infancy is a major cause of persistent hypoglycaemia in the newborn period. Transient mild self-limiting hyperinsulinaemia and hypoglycaemia have been described in neonates born to mothers taking ritodrine therapy for premature labour. Ritodrine crosses the placental barrier and enters the fetal circulation readily but the mechanism of how it causes hyperinsulinaemia and hypoglycaemia is unclear. We report the case of severe prolonged hyperinsulinaemic hypoglycamia in a neonate born to a mot… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
6
0

Year Published

2006
2006
2023
2023

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 14 publications
(6 citation statements)
references
References 47 publications
0
6
0
Order By: Relevance
“…The times of additional interventions in these case reports vary greatly from within the first 36 hours of life 23 to 7 to 10 days of life. 24 It may be prudent to delay additional therapies as long as possible (up to 14 days of life) to allow the transient forms of hypoglycemia to resolve in order not to expose infants to unnecessary drug therapy. Other than the infant who continues to experience consistent episodes of hypoglycemia or requires persistently high dextrose concentrations (>D25%), most infants should remain on dextrose infusions for at least 7 to 10 days before the addition of other therapeutic options is considered.…”
Section: Dextrosementioning
confidence: 99%
See 1 more Smart Citation
“…The times of additional interventions in these case reports vary greatly from within the first 36 hours of life 23 to 7 to 10 days of life. 24 It may be prudent to delay additional therapies as long as possible (up to 14 days of life) to allow the transient forms of hypoglycemia to resolve in order not to expose infants to unnecessary drug therapy. Other than the infant who continues to experience consistent episodes of hypoglycemia or requires persistently high dextrose concentrations (>D25%), most infants should remain on dextrose infusions for at least 7 to 10 days before the addition of other therapeutic options is considered.…”
Section: Dextrosementioning
confidence: 99%
“…This treatment approach has been discussed more recently in the literature in patients fro whom other therapeutic options have failed; however, only 4 patients have been described in the published case series. 24,48,49 Nifedipine was initiated at 0.25 to 0.3 mg/kg/day, orally, divided every 8 hours. Doses were increased by 0.1 mg/kg/day until patients were euglycemic and dextrose was weaned.…”
Section: Nifedipinementioning
confidence: 99%
“…None of the infants were prenatally exposed to maternal drugs associated with neonatal hyperinsulinism, such as ritodrine or thiazide diuretics [16]. Perinatal complications that commonly predispose to prolonged neonatal hyperinsulinism, such as IUGR or severe asphyxia [6,7,17] were absent in all infants.…”
Section: Discussionmentioning
confidence: 99%
“…71 In one case, hypoglycemia was severe and recurrent. 72 Dose-response gradient: no dose effect has been evaluated.…”
Section: Selective and Nonselective β-Blockers (β-Adrenergic Receptor...mentioning
confidence: 99%
“…74 Management: the management of severe transient hyperinsulinemic hypoglycemia in a neonate born to a mother taking ritodrine from 16 weeks of gestation for preterm labor required treatment with continuous IV glucose infusion (up to 12 mg/kg/min) and oral nifedipine. 72 Quality of the studies: the available data derive mainly from retrospective studies or case series with small sample sizes.…”
Section: Selective and Nonselective β-Blockers (β-Adrenergic Receptor...mentioning
confidence: 99%